Based on PIC/S Annex 1 “Manufacture of Sterile Medicinal Products”, it is particularly important to ensure the quality and safety of sterile medicinal products throughout their manufacturing process. QC has played an essential role in the control and reduction of contamination by microorganisms, particulates and endotoxins/pyrogens.
Aseptic filling is the final production stage in the pharmaceutical industry and one of the most critical steps. However, the production process for proteins and new therapeutic modalities in aseptic filling faces numerous difficulties and challenges. To further advance the pharmaceutical industry and enhance the understanding of advanced aseptic filling processes among industry professionals and experts, Amaran and Cytiva will co-host the "Advanced Aseptic Processing Technology for Proteins and New Modalities" Workshop, scheduled to be held on Thursday, November 7, 2024, in Zhubei City.
Amaran Biotech, a leading Taiwanese CDMO (Contract Development & Manufacturing Organization) offering comprehensive pharmaceutical development and manufacturing solutions, is making its debut at BioJapan 2024 in Yokohama from October 9 to 11. The company is participating as part of Taiwan’s Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) delegation. Amaran Biotech will showcase its services at the Taiwan Pavilion (Booth No. B-56), including its vaccine adjuvant AB-801 (QS-21), drug substance manufacturing, drug product manufacturing, and stability study and analytical science services. Visitors are invited to meet with Amaran Biotech's representatives at the event.
In the field of immunology and vaccine development, adjuvants are vital components that enhance the immune response elicited by vaccines. One such adjuvant, QS-21, a natural product extracted from the bark of the soap bark tree (Quillaja saponaria), is an attractive candidate for use in vaccines.